Abstract: Crystals of the compound represented by formula (1), a method for the production thereof, and a method for producing an antibody-drug conjugate using the crystals.

Abstract: A method for producing a compound represented by formula (C) wherein R1 represents an amino group protected with a protecting group, the method comprising a step of subjecting a compound represented by formula (B) wherein R1 represents the same meaning as above, to intramolecular cyclization to convert the compound into the compound represented by formula (C).

Abstract: A method for producing a compound represented by formula (C) wherein R1 represents an amino group protected with a protecting group, the method comprising a step of subjecting a compound represented by formula (B) wherein R1 represents the same meaning as above, to intramolecular cyclization to convert the compound into the compound represented by formula (C).

Abstract: A method for producing a compound represented by formula (C) wherein R1 represents an amino group protected with a protecting group, the method comprising a step of subjecting a compound represented by formula (B) wherein R1 represents the same meaning as above, to intramolecular cyclization to convert the compound into the compound represented by formula (C).

Abstract: Crystals of the compound represented by formula (1), a method for the production thereof, and a method for producing an antibody-drug conjugate using the crystals.

Abstract: A method for producing a compound represented by formula (C) wherein R1 represents an amino group protected with a protecting group, the method comprising a step of subjecting a compound represented by formula (B) wherein R1 represents the same meaning as above, to intramolecular cyclization to convert the compound into the compound represented by formula (C).

Abstract: An optically active 4,4-di-substituted oxazolidine compound having the formula (I) wherein R1 represents a substituted C1-C3 alkyl group, a substituted C2-C3 alkenyl group, a formyl group, a hydroxymethyl group, a group of the formula COOR, a halogenated methyl group, a phosphonium methyl group; R represents a C1-C6 alkyl group, a C2-C6 alkenyl group, a phenyl group or a benzyl group; R2 represents a C1-C6 alkyl group, a C3-C10 cycloalkyl group, or a phenyl group; R3 represents a C2-C6 alkanoyl group, a C1-C6 alkyloxycarbonyl group, a benzoyl group, a phenyloxycarbonyl group or a benzyloxycarbonyl group and R4 represents a C1-C6 alkyl group or a C2-C6 alkenyl group.

Abstract: An optically active 4,4-di-substituted oxazolidine compound having the formula (I) wherein R1 represents a substituted C1-C3 alkyl group, a substituted C2-C3 alkenyl group, a formyl group, a hydroxymethyl group, a group of the formula COOR, a halogenated methyl group, a phosphonium methyl group; R represents a C1-C6 alkyl group, a C2-C6 alkenyl group, a phenyl group or a benzyl group; R2 represents a C1-C6 alkyl group, a C3-C10 cycloalkyl group, or the like or a phenyl group; R3 represents a C2-C6 alkanoyl group, a C1-C6 alkyloxycarbonyl group, a benzoyl group, a phenyloxycarbonyl group or a benzyloxycarbonyl group and R4 represents a C1-C6 alkyl group or a C2-C6 alkenyl group.

Abstract: A repeat interval, the number of encoding and the number of excitations are set in a processor by inputting from a keyboard before the start of image acquisition. The image acquisition duration is calculated using these set parameters, and the value corresponding to the image acquisition duration is set in a timer. The timer performs down-counting during image acquisition. A remaining image acquisition duration generated from the timer is displayed on a display and/or is output as voice signals from a voice output unit. Informing the patient of the time remaining until completion of image acquisition reduces the patient's anxiety and thus reduces motion artifacts.